4.7 Review

Positron Emission Tomography Image-Guided Drug Delivery: Current Status and Future Perspectives

期刊

MOLECULAR PHARMACEUTICS
卷 11, 期 11, 页码 3777-3797

出版社

AMER CHEMICAL SOC
DOI: 10.1021/mp500173s

关键词

positron emission tomography; image-guided drug delivery; cancer; theranostics; molecular imaging; personalized medicine

资金

  1. University of Wisconsin Madison
  2. National Institutes of Health NIBIB/NCI [1R01CA169365, P30CA014520]
  3. Department of Defense [W81XWH-11-1-0644]
  4. American Cancer Society [125246-RSG-13-099-01-CCE]
  5. Fulbright Scholar Program [1831/FNPDR/2013]

向作者/读者索取更多资源

Positron emission tomography (PET) is an important modality in the field of molecular imaging, which is gradually impacting patient care by providing safe, fast, and reliable techniques that help to alter the course of patient care by revealing invasive, de facto procedures to be unnecessary or rendering them obsolete. Also, PET provides a key connection between the molecular mechanisms involved in the pathophysiology of disease and the according targeted therapies. Recently, PET imaging is also gaining ground in the field of drug delivery. Current drug delivery research is focused on developing novel drug delivery systems with emphasis on precise targeting, accurate dose delivery, and minimal toxicity in order to achieve maximum therapeutic efficacy. At the intersection between PET imaging and controlled drug delivery, interest has grown in combining both these paradigms into clinically effective formulations. PET image-guided drug delivery has great potential to revolutionize patient care by in vivo assessment of drug biodistribution and accumulation at the target site and real-time monitoring of the therapeutic outcome. The expected end point of this approach is to provide fundamental support for the optimization of innovative diagnostic and therapeutic strategies that could contribute to emerging concepts in the field of personalized medicine. This review focuses on the recent developments in PET image-guided drug delivery and discusses intriguing opportunities for future development. The preclinical data reported to date are quite promising, and it is evident that such strategies in cancer management hold promise for clinically translatable advances that can positively impact the overall diagnostic and therapeutic processes and result in enhanced quality of life for cancer patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据